Traci Umberger Sells 3,580 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 3,580 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.04, for a total transaction of $86,063.20. Following the completion of the sale, the insider directly owned 195,825 shares of the company’s stock, valued at approximately $4,707,633. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $26.40 on Friday. The stock’s 50-day moving average is $22.96 and its two-hundred day moving average is $22.57. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -10.91 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a 1 year low of $14.30 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analysts Set New Price Targets

KMTS has been the subject of a number of research reports. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $27.83.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Seven Grand Managers LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at about $2,652,000. Eventide Asset Management LLC increased its position in Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares during the period. Sei Investments Co. increased its position in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares during the period. Summit Partners Public Asset Management LLC purchased a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $9,282,000. Finally, UBS Group AG raised its stake in shares of Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after buying an additional 69,908 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.